Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?
Open Access
- 15 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (12), 3646-3650
- https://doi.org/10.1158/1078-0432.ccr-07-4481
Abstract
Circulating tumor cells (CTC) can be identified and characterized in blood of patients with many solid tumors, particularly breast cancer. Between 10% and 30% of patients with stage I to III breast cancer and 50% to 70% of women with metastatic breast cancer have detectable CTCs. In both cases, presence and elevation of CTCs are associated with worse prognosis. In the metastatic setting, persistent CTC after 3 to 5 weeks of a new therapy seem to indicate lack of activity of that regimen, and an ongoing prospective randomized clinical trial is addressing the relative worth of changing to an alternative treatment rather than waiting for classic clinical and radiologic evidence of progression. Recent technical advances offer the promise of further genotyping and phenotyping for important tumor-associated genes and proteins.Keywords
This publication has 30 references indexed in Scilit:
- Isolation of rare circulating tumour cells in cancer patients by microchip technologyNature, 2007
- The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancerAnnals Of Oncology, 2007
- Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic valueClinical & Experimental Metastasis, 2007
- uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesProceedings of the National Academy of Sciences of the United States of America, 2006
- Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer PatientsJournal of Clinical Oncology, 2006
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- HER-2 gene amplification can be acquired as breast cancer progressesProceedings of the National Academy of Sciences of the United States of America, 2004